JPWO2019086476A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019086476A5
JPWO2019086476A5 JP2020524308A JP2020524308A JPWO2019086476A5 JP WO2019086476 A5 JPWO2019086476 A5 JP WO2019086476A5 JP 2020524308 A JP2020524308 A JP 2020524308A JP 2020524308 A JP2020524308 A JP 2020524308A JP WO2019086476 A5 JPWO2019086476 A5 JP WO2019086476A5
Authority
JP
Japan
Prior art keywords
cells
selectivity
population
test compound
interactions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020524308A
Other languages
English (en)
Other versions
JP2021500912A (ja
JP2021500912A5 (ja
JP7478094B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/079746 external-priority patent/WO2019086476A1/en
Publication of JP2021500912A publication Critical patent/JP2021500912A/ja
Publication of JP2021500912A5 publication Critical patent/JP2021500912A5/ja
Publication of JPWO2019086476A5 publication Critical patent/JPWO2019086476A5/ja
Application granted granted Critical
Publication of JP7478094B2 publication Critical patent/JP7478094B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

さらに、本発明の方法は、技術分野で実施される方法と異なり、細胞の合計集団を構成する細胞集団に関して、試験化合物の選択性を決定する前に、細胞の合計集団を構成する細胞集団の分離を必要としない。そのため、本発明の方法は、その選択性を決定するために、分離された細胞集団に対する試験化合物の効果に依存するだけでなく、細胞の複合集団に含まれる細胞の相互作用にも考慮する。したがって、本発明の方法は驚くべきことに、細胞の混合物において試験化合物の選択性の測定を可能にすることができ、それにより得られる選択性は、異なる測定値間で細胞数の変化例に対して本質的に強固であり、本質的に制御され、細胞の合計集団に含まれる異なる細胞集団間の相互作用を考慮する。
JP2020524308A 2017-10-31 2018-10-30 試験化合物の選択性を決定する方法 Active JP7478094B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17199353.8 2017-10-31
EP17199353 2017-10-31
PCT/EP2018/079746 WO2019086476A1 (en) 2017-10-31 2018-10-30 Methods for determining selectivity of test compounds

Publications (4)

Publication Number Publication Date
JP2021500912A JP2021500912A (ja) 2021-01-14
JP2021500912A5 JP2021500912A5 (ja) 2021-12-02
JPWO2019086476A5 true JPWO2019086476A5 (ja) 2023-07-12
JP7478094B2 JP7478094B2 (ja) 2024-05-02

Family

ID=60413039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524308A Active JP7478094B2 (ja) 2017-10-31 2018-10-30 試験化合物の選択性を決定する方法

Country Status (10)

Country Link
US (1) US20210181183A1 (ja)
EP (1) EP3704484A1 (ja)
JP (1) JP7478094B2 (ja)
KR (1) KR20200079296A (ja)
CN (1) CN111295588A (ja)
AU (1) AU2018359500A1 (ja)
CA (1) CA3079134A1 (ja)
IL (1) IL274074A (ja)
SG (1) SG11202002570WA (ja)
WO (1) WO2019086476A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201806188D0 (en) * 2018-04-16 2018-05-30 Bailey David Stanley Methods for cell profiling
CA3119297A1 (en) * 2018-11-14 2020-05-22 Dana-Farber Cancer Institute, Inc. Determining treatment response in single cells
CN116083512A (zh) * 2021-12-28 2023-05-09 珠海市藤栢医药有限公司 受试物的生物活性的检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE129019T1 (de) * 1990-05-07 1995-10-15 Dade Int Inc Verfahren und vorrichtung zur ausführung des zytotoxizitätsassays auf tumorzellen.
FR2754544B1 (fr) 1996-10-10 1998-11-06 Lorraine Laminage Tole aluminiee a faible emissivite
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US6576291B2 (en) 2000-12-08 2003-06-10 Massachusetts Institute Of Technology Preparation of nanocrystallites
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
US20030027229A1 (en) * 2001-06-01 2003-02-06 Cytovia, Inc. Methods of identifying potentially therapeutically selective and effective anti-cancer agents that are inducers of apoptosis
CA2453450A1 (en) 2001-07-20 2003-11-06 Quantum Dot Corporation Luminescent nanoparticles and methods for their preparation
US7981667B2 (en) 2003-05-07 2011-07-19 Indiana University Research And Technology Corporation Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto
KR100657891B1 (ko) 2003-07-19 2006-12-14 삼성전자주식회사 반도체 나노결정 및 그 제조방법
WO2005061707A1 (ja) 2003-12-24 2005-07-07 Kyowa Hakko Kogyo Co., Ltd. 癌細胞のEg5阻害剤に対する感受性を判定する方法
WO2006033972A2 (en) * 2004-09-15 2006-03-30 Protometrix, Inc. Protein arrays and methods of use thereof
AU2010206843B2 (en) * 2009-01-20 2015-01-29 The Board Of Trustees Of The Leland Stanford Junior University Single cell gene expression for diagnosis, prognosis and identification of drug targets
BRPI1012980A2 (pt) 2009-05-19 2016-03-29 Vivia Biotech Sl dispositivo e métodos para analisar a capacidade de resposta celular e a resposta de células neoplásticas a drogas
US20110129822A1 (en) 2009-12-01 2011-06-02 Precision Therapeutics, Inc. Multi drug response markers for breast cancer cells
WO2011149013A1 (ja) 2010-05-26 2011-12-01 株式会社Ｒｅｉメディカル 癌組織由来細胞塊または癌細胞凝集塊の薬剤または放射線感受性評価方法
US20140093953A1 (en) * 2012-10-01 2014-04-03 The Regents Of The University Of Michigan Non-adherent cell support and manufacturing method
EP3198276B1 (en) 2014-09-24 2023-09-20 Exscientia GmbH Monolayer of pbmcs or bone-marrow cells and uses thereof
WO2017143287A1 (en) * 2016-02-18 2017-08-24 University Of South Florida Methods of screening drugs for cancer treatment using cells grown on a fiber-inspired smart scaffold

Similar Documents

Publication Publication Date Title
JP2019176880A5 (ja)
Chow et al. The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer
Iborra-Egea et al. Molecular signature of cardiogenic shock
WO2018060739A3 (en) Assay for distinguishing between sepsis and systemic inflammatory response syndrome
Waterhouse et al. Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation
Yamasaki et al. TARP γ-2 and γ-8 differentially control AMPAR density across schaffer collateral/commissural synapses in the hippocampal CA1 area
JP2016511406A5 (ja)
WO2009073505A3 (en) Methods for processing tandem mass spectral data for protein sequence analysis
WO2017194613A3 (en) Method, array and use thereof
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
JP2012523838A5 (ja)
WO2021183917A8 (en) Systems and methods for deconvolution of expression data
Henderson et al. Mice with altered α-actinin-4 expression have distinct morphologic patterns of glomerular disease
JPWO2019086476A5 (ja)
Narita et al. The hybrid type polyketide synthase SteelyA is required for cAMP signalling in early Dictyostelium development
KR101516086B1 (ko) 대사체 분석을 이용한 류마티스 관절염 진단방법
WO2020087037A3 (en) Disease stratification of liver disease and related methods
MX2020009705A (es) Metodos para la deteccion del riesgo de enfermedad renal cronica en un sujeto y metodo implementado por computadora.
WO2017032815A3 (en) Biomarkers for cardiometabolic diseases
Ploegstra et al. Long-term outcome of children with newly diagnosed pulmonary arterial hypertension: results from the global TOPP registry
EP1776480A2 (fr) Marqueurs et procedes pour le depistage prenatal d'anomalies chromosomiques
WO2018060523A3 (en) Computer device for detecting an optimal candidate compound and methods thereof
Testa et al. Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression
Frederiksen et al. Multidimensional clusters of CD4+ T cell dysfunction are primarily associated with the CD4/CD8 ratio in chronic HIV infection
Nakazato et al. Blood folate concentrations analyzed by microbiological assay and chemiluminescent immunoassay methods